One-Year Effect on Levodopa Equivalent Daily Dose of Thalamic VIM Nucleus Stimulation Compared to Subthalamic Nucleus Stimulation in Patients With Parkinson's Disease

Launched by CENTRAL HOSPITAL, NANCY, FRANCE · Apr 12, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how two different types of deep brain stimulation (DBS) affect the amount of medication needed for people with Parkinson's disease. Specifically, it compares stimulation of the thalamic VIM nucleus, which is usually used to help with tremors, to stimulation of the subthalamic nucleus, which is thought to reduce medication needs more effectively. The researchers want to see if the VIM stimulation can also help lower the daily dose of medications that patients take for their condition.

To be eligible for this study, participants must be patients with Parkinson's disease who have undergone surgery for either type of DBS at a specific hospital in Nancy, France, between 2014 and 2024. Unfortunately, patients who do not have Parkinson's disease, those who haven't started treatment with certain medications, or those who had surgery at a different location will not be able to participate. While the study is not yet recruiting participants, those who join can expect to contribute to important research that may help improve treatment options for people with Parkinson's disease in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinical diagnosis of Parkinson's disease
• • Underwent surgery for subthalamic nucleus (STN) or ventral intermediate nucleus (VIM) deep brain stimulation
• • Surgery performed at CHRU of Nancy
• • Surgery performed between 2014 (DxCare implementation) and 2024
• Exclusion Criteria:
• • No clinical diagnosis of Parkinson's disease
• • No initial dopaminergic treatment
• • Surgery not performed at CHRU of Nancy
• • Death within 1 year following surgery